Announcement
30 Nov 2020
In November 2020, the European Union signed an Advanced Purchase Agreement (APA) with CureVac with respect to the European doses of the company’s COVID-19 vaccines. The agreement was published in January 2021.
Source
Sign in to access
Number of interventions
1
1 certainly harmful
0 likely harmful
0 liberalising
List of interventions
Implementation date
30 Nov 2020
Revocation date:
No revocation date
Updated: 30 Nov 2020
Local operations incentive
In force
On 30 November 2020, the EU and CureVac signed an Advanced Purchase Agreement (APA) for the production, purchase and supply of the company’s COVID-19 vaccine. However, it was not until January 2021...
Sign in to see more
Related State Acts
29 Jan 2021
EU: Commission adopts temporary export authorisation for COVID-19 vaccines
20 Nov 2020
EU: Localisation requirement included in the Advanced Purchase Agreement with BioNTech-Pfizer
18 Sep 2020
EU: Advanced Purchase Agreement with Sanofi-GSK includes localisation incentive
27 Aug 2020
EU: COVID-19 Advanced Purchase Agreement with AstraZeneca includes localisation requirement
27 Jun 2020
Germany: EIB and European Commission provide financing for vaccine development and expansion of manufacturing
Threads
See all
This state act is not part of any Thread yet.